PMS37 RATES OF REAL-WORLD TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE

Psoriatic arthritis: treatment strategies using biologic agents.

The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently available anti-TNFα blocking agents (etanercept, infliximab, adalimu...

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

Biologic therapy of psoriatic arthritis.

Psoriatic arthritis is now recognized as a potentially serious and disabling disease. Traditional therapies have not been very effective in controlling signs and symptoms or preventing progression of damage. Based on the pathogenesis of the disease new therapies have been introduced, particularly anti-TNF agents and anti-T cell agents. Several of those have shown excellent responses in clinical...

Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population

INTRODUCTION The aim of this study was to describe factors associated with initiating a biologic as monotherapy vs in combination with a conventional disease-modifying antirheumatic drug (DMARD) in biologic-naive patients with rheumatoid arthritis (RA) enrolled in the Corrona registry. METHODS First biologic initiations were classified as monotherapy (Bio MT) or combination therapy (Bio CMB)....

Treatment Persistence With Subcutaneous Biologic Therapies in Patients With Psoriatic Arthritis (Psa).

Background • Psoriatic arthritis (PsA) is an inflammatory peripheral and/or axial arthritis associated with psoriasis, usually seronegative for rheumatoid factors1 • Patients with PsA also have debilitating skin disease, and nearly half may also have a spinal disease.2 PsA is estimated to affect 2.0% to 3.0% of the general population3 • To date, few studies have examined treatment persistence o...